Friday, 28 October 2016

Cellmid Ltd to update on capital raising

Cellmid's record deals for its FGF5 inhibitor male pattern baldness items

The ASX has allowed additional time in the frame on a willful suspension, taking after an exchanging end.

The organization said that it will exhort the market when it finishes arrangements, which is required to happen inside a few exchanging days.

Record deals

Cellmid as of late accomplished record deals for its FGF5 inhibitor male pattern baldness items amid the primary quarter of the 2017 money related year.

Surprisingly, deals surpassed the million-dollar stamp for the quarter

Australian deals developed by 115%, with the new national publicizing program indicating solid results.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.